Elucigene CFEU2v1 kit receives Health Canada Approval
We are delighted to announce that the Elucigene CFEU2v1 is now approved for use by Health Canada.
CFEU2v1 is rapidly becoming the market leading product for CFTR testing. Our kit uses ARMS technology to detect the 50 most common CFTR mutations found in the European population. Using data published by the WHO in 2004, this gives a detection coverage of 86% in the Canadian population, making CFEU2v1 a cost effective first line test for Cystic Fibrosis.
We are looking forward to introducing this kit in to the Canadian market!
Data source: WHO Human Genetics Programme. (2004). The molecular genetic epidemiology of cystic fibrosis : report of a joint meeting of WHO/IECFTN/ICF(M)A/ECFS, Genoa, Italy, 19 June 2002. Geneva : World Health Organization.